Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- GLPG.AS
- Price
- 26.20
- Stock movement down
- -0.40 (-1.50%)
- Company name
- Galapagos N.V.
- Exchange
- (AS ,
- Currency
- EUR )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.73B
- Ent value
- 2.73B
- Price/Sales
- 6.02
- Price/Book
- 0.71
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -13.47%
- 1 year return
- 2.58%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-12-16
DIVIDENDS
GLPG.AS does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 6.02 |
| Price to Book | 0.71 |
| EV to Sales | 9.50 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 65.90M |
| EPS (TTM) | - |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | - |
| Gross profit (TTM) | - |
| Operating income (TTM) | - |
| Net income (TTM) | - |
| EPS (TTM) | - |
| EPS (1y forward) | -0.83 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 64.46M |
| Net receivables | 45.33M |
| Total current assets | 3.16B |
| Goodwill | 0.00 |
| Intangible assets | 7.42M |
| Property, plant and equipment | 0.00 |
| Total assets | 3.51B |
| Accounts payable | 100.63M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 366.56M |
| Total liabilities | 1.06B |
| Shareholder's equity | 2.45B |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | - |
| Capital expenditures (TTM) | - |
| Free cash flow (TTM) | - |
| Dividends paid (TTM) | - |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | - |
| Return on Invested Capital | - |
| Cash Return on Invested Capital | - |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 26.50 |
| Daily high | 26.58 |
| Daily low | 26.06 |
| Daily Volume | 58K |
| All-time high | 249.50 |
| 1y analyst estimate | 30.34 |
| Beta | -0.05 |
| EPS (TTM) | - |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 23 Feb 2026 |
Downside potential
Loading...
Downside potential data
| GLPG.AS | S&P500 | |
| Current price drop from All-time high | -89.50% | -1.49% |
| Highest price drop | -91.58% | -19.00% |
| Date of highest drop | 7 Apr 2025 | 8 Apr 2025 |
| Avg drop from high | -89.68% | -2.63% |
| Avg time to new high | - | 6 days |
| Max time to new high | 304 days | 89 days |
COMPANY DETAILS
Marketcap
1.73B
Marketcap category
Small-cap
Description
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Employees
704
Website
Investor relations
-
SEC filings
CEO
Country
Netherlands
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
High complete response rates and minimal residual disease (MRD) negativity, with durable responses, in high-risk mantle cell lymphoma (MCL) with GLPG5101, a fresh, early memory-enriched CAR T-cell the...
December 8, 2025
Mechelen, Belgium; November 26, 2025, 07:30 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received transparency notifications from Bank of America. Pursuant to Belgian transparen...
November 26, 2025
Galapagos (ENXTAM:GLPG) shares have been moving quietly, and investors might be re-examining the company’s fundamentals as they consider mixed returns over the past year and ongoing challenges in reve...
November 11, 2025
Galapagos NV (GLPG) outlines its strategic reorganization and financial outlook while leveraging partnerships for future growth.
November 6, 2025
Strategic review process concluded with intention to wind down cell therapy business, representing optimal capital allocation pathway to support a stronger and sustainable future for GalapagosContinue...
November 5, 2025
Oral presentation of GLPG5101 data from the ATALANTA-1 study in patients with high-risk relapsed/refractory mantle cell lymphoma Two abstracts featuring new Phase 2 data highlight the potential of CAR...
November 3, 2025
New Directors bring strong financial leadership, capital allocation, and business development expertise to the Board Mechelen, Belgium; October 30, 2025, 21:01 CET — Galapagos NV (Euronext & NASDAQ: G...
October 30, 2025
Mechelen, Belgium; October 23, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present new in vitro pharmacological data from its selective TYK2 inhibitor, GLPG366...
October 23, 2025
Galapagos NV recently announced its intention to wind down its cell therapy business, following a comprehensive strategic review and impacting approximately 365 employees across multiple global sites....
October 23, 2025
The latest in a trend of companies stepping back from cell and gene therapies amid regulatory uncertainty and manufacturing challenges.
October 22, 2025
Next page